

**Notice of Price Adjustment to 340B Covered Entities That Purchased ZEVALIN®
from Q3 2009 through Q2 2020**

July 3, 2020

Spectrum Pharmaceuticals, Inc. (Spectrum) has restated the 340B ceiling price for its drug ZEVALIN® (ibritumomab tiuxetan) injection, for intravenous use, NDCs 68152-0104-04 and 68152-0103-03, for the period from Q3 2009 through Q2 2020.

Covered entities that purchased Zevalin directly from Spectrum for use under the 340B program during this period may be eligible for a refund.

Spectrum requests that any 340B covered entity that made such purchases that were eligible for 340B pricing submit appropriate requests for refunds using the process described below. Refund requests must be received on or before December 31, 2020. Spectrum will promptly review all such refund requests that are timely received.

Spectrum has asked the Office of Pharmacy Affairs (OPA) to post this Notice on OPA's public website to give affected covered entities the opportunity to request refunds.

Refund Request Process:

1. Please complete the Refund Request Form that is included at the end of this Notice. To be eligible for a refund, the Refund Request Form must be accompanied by a copy of the covered entity's Form W-9 and evidence of the purchase(s) and purchase price(s).
2. Send the completed form and accompanying documentation electronically to Zevalin340BRefund@sppirx.com.
3. If you have any questions or require assistance with respect to the refund request, please contact Gregg Kunzi, Spectrum's Deputy General Counsel, at gregg.kunzi@sppirx.com, or by phone at (702) 835-6308, during regular business hours.
4. To be eligible for a refund, the Refund Request Form must be received on or before December 31, 2020.

